 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Neoadjuvant chemoradiotherapy plus Galunisertib improves complete remission rates for locally advanced rectal cancer!

Lancet Oncol: Neoadjuvant chemoradiotherapy plus Galunisertib improves complete remission rates for locally advanced rectal cancer!

 Last Update: 2022-10-02
 Source: Internet
 Author: User

Tags

1 4 gas

primary dysmenorrhea treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

TGF-β is an immunosuppressive cytokine whose expression levels are upregulated

The study aimed to test the hypothesis that the addition of the TGF-β type I receptor kinase inhibitor Galunisertib in neoadjuvant chemoradiotherapy increased the rate

This is a single-armed, phase 2 study initiated by researchers who enrolled patients aged 18 years and older with

Between 19 October 2016 and 31 August 2020, a total of 38 patients

The most common grade 3 adverse events during treatment were diarrhea (16%) and hematologic toxicity (18%)

In summary, the addition of Galunisertib to the neoadjuvant chemoradiotherapy regimen increased the complete remission rate to 32% in patients with locally advanced rectal cancer and was well tolerated and warranted further randomized trials to evaluate

Original Source:

Tomoko Yamazaki, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.